DYN — Dyne Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818794 ·
Last close
$16.37
Market Cap
$3.06B
52W High
$27.31
52W Low
$13.73
ADV30
3,517,506
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -181,661,000 | -178,556,000 | 994,013,000 | 676,114,000 | 291,862,000 |
| Mar 2026 | 0 | — | -125,276,000 | -120,854,000 | 1,079,950,000 | 753,102,000 | 214,895,000 |
| Dec 2025 | 0 | — | -116,129,000 | -111,955,000 | 1,186,958,000 | 893,369,000 | 214,829,000 |
| Sep 2025 | 0 | — | -113,892,000 | -108,041,000 | 867,059,000 | 573,610,000 | 175,276,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-477,819,000
Investing CF
$-44,170,000
Financing CF
$713,466,000
CapEx
$-21,404,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.33
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,695,552,000
Inventory
—
Receivables
—
ST Investments
$222,361,000
EBIT TTM
$-504,511,000
Pretax Income TTM
$-519,406,000
Interest Exp TTM
$14,895,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -468,184,000 | -446,214,000 | 1,186,958,000 | 214,829,000 | 972,129,000 | -403,207,000 |
| Dec 2024 | 0 | -343,886,000 | -317,418,000 | 691,234,000 | 61,396,000 | 629,838,000 | -292,369,000 |
| Dec 2023 | 0 | -242,162,000 | -235,937,000 | 165,082,000 | 73,790,000 | 91,292,000 | -188,158,000 |
| Dec 2022 | 0 | -170,962,000 | -168,099,000 | 306,325,000 | 53,961,000 | 252,364,000 | -153,645,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-451,707,000
OpCashFlow TTM
—
Assets (Latest)
$1,079,950,000
Forward EPS
$-3.33
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | $3.08B | $24.49 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.03B | $27.20 | — |
| RCUS | Arcus Biosciences, Inc. | $3.00B | $23.83 | — |
| ELVN | Enliven Therapeutics, Inc. | $2.98B | $40.63 | — |
| VKTX | Viking Therapeutics, Inc. | $3.23B | $27.73 | — |
News headlines (Yahoo Finance, 1h cache)
Why Dyne Therapeutics (DYN) Is Back In The Spotlight
2026-10-07 14:12 · Yahoo
Dyne Therapeutics stock rises on positive DM1 trial results
2026-09-29 21:23 · Yahoo
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
2026-09-29 20:05 · Yahoo
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-17 20:05 · Yahoo
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
2026-09-17 16:13 · Yahoo
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
2026-09-09 15:41 · Yahoo
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
2026-09-08 10:50 · Yahoo
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
2026-09-03 11:30 · Yahoo
Top 4 Healthcare Stocks Backed by Raymond James Analysts
2026-10-08 14:09 · Yahoo
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says
2026-09-09 15:10 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-06 16:15:03 | 2026-10-02 | Posner Brian S | Dir | P - Purchase | 16 | 2500 | 40000 |